Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2022 Q1- Text added to 2022 Q2
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. senior Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. senior Avg
|
New words:
adenocarcinoma, afatinib, AstraZeneca, AZN, borrowing, castration, CI, Cl, cohort, deducting, deteriorate, downturn, ductal, fallen, fulfill, heard, indemnification, ORR, osimertinib, prostate, Qualitative, Quantitative, reagent, recession, revocation, robust, Tagrisso, unemployment, Unstable, XIII
Removed:
multicenter, persuading, ranging, updating, website
Valuein 2022 Q1 filing- Value in 2022 Q2 filing
Original filings
Filing view